Innoviva (INVA) Interest Coverage Ratio Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.80% |
| Sep 30, 2025 | -14.03% |
| Jun 30, 2025 | -8.85% |
| Mar 31, 2025 | -12.20% |
| Sep 30, 2024 | -10.48% |
| Jun 30, 2024 | -5.97% |
| Mar 31, 2024 | -16.59% |
| Sep 30, 2023 | 12.18% |
| Jun 30, 2023 | -17.37% |
| Mar 31, 2023 | -19.94% |
| Sep 30, 2022 | -82.67% |
| Jun 30, 2022 | -21.46% |
| Mar 31, 2022 | -26.74% |
| Sep 30, 2021 | 56.09% |
| Jun 30, 2021 | 59.56% |
| Mar 31, 2021 | -23.46% |
| Dec 31, 2020 | -24.96% |
| Sep 30, 2020 | 95.30% |
| Jun 30, 2020 | 111.43% |
| Mar 31, 2020 | 210.25% |
| Dec 31, 2019 | 332.77% |
| Sep 30, 2019 | 79.77% |
| Jun 30, 2019 | 73.05% |
| Mar 31, 2019 | 26.67% |
| Dec 31, 2018 | 42.29% |
| Sep 30, 2018 | 36.37% |
| Jun 30, 2018 | 44.24% |
| Mar 31, 2018 | 19.49% |
| Dec 31, 2017 | 15.60% |
| Sep 30, 2017 | 17.95% |
| Jun 30, 2017 | 16.70% |
| Mar 31, 2017 | -47.45% |
| Dec 31, 2016 | 16.24% |
| Sep 30, 2016 | 16.10% |
| Jun 30, 2016 | 16.27% |
| Mar 31, 2016 | 15.93% |
| Dec 31, 2015 | 16.12% |
| Sep 30, 2015 | 15.43% |
| Jun 30, 2015 | 15.22% |